{"id":58311,"date":"2026-02-27T20:09:42","date_gmt":"2026-02-27T12:09:42","guid":{"rendered":"https:\/\/flcube.com\/?p=58311"},"modified":"2026-02-27T20:09:43","modified_gmt":"2026-02-27T12:09:43","slug":"gan-lees-insulin-biosimilars-win-chmp-positive-opinion-bysumlog-and-dazparda-near-eu-market-entry","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58311","title":{"rendered":"Gan &amp; Lee&#8217;s Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry"},"content":{"rendered":"\n<p><strong>Gan &amp; Lee Pharmaceuticals (<a href=\"https:\/\/www.google.com\/finance\/quote\/603087:SHA\">SHA:\u202f603087<\/a>)<\/strong> and its <strong>European subsidiary Gan &amp; Lee Europe<\/strong> announced that the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> of the <strong>European Medicines Agency (EMA)<\/strong> issued a <strong>positive opinion<\/strong> recommending approval for two insulin biosimilars: <strong>Bysumlog (insulin lispro)<\/strong> and <strong>Dazparda (insulin aspart)<\/strong>. Upon <strong>European Commission (EC) ratification<\/strong>, the products will be marketed across <strong>EU member states plus Iceland, Liechtenstein, and Norway<\/strong>, providing <strong>biosimilar alternatives<\/strong> to <strong>Eli Lilly&#8217;s Humalog<\/strong> and <strong>Novo Nordisk&#8217;s NovoRapid<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Gan &amp; Lee Pharmaceuticals (SHA:\u202f603087) + Gan &amp; Lee Europe<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Bysumlog (insulin lispro); Dazparda (insulin aspart)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Rapid\u2011acting insulin biosimilars<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>EMA CHMP (positive opinion); EC (pending final approval)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Diabetes (adults, adolescents, children \u2265\u202f1 year)<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>EU + Iceland, Liechtenstein, Norway<\/td><\/tr><tr><td><strong>Originator References<\/strong><\/td><td>Humalog (Eli Lilly); NovoRapid (Novo Nordisk)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-partnership-sandoz-agreement\">Commercial Partnership \u2013 Sandoz Agreement<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner<\/strong><\/td><td>Sandoz (Novartis generics\/biosimilars division)<\/td><\/tr><tr><td><strong>Products Covered<\/strong><\/td><td>3 insulin biosimilars: insulin glargine, insulin lispro, insulin aspart<\/td><\/tr><tr><td><strong>Sandoz Responsibilities<\/strong><\/td><td>Commercialization and sales in Europe + specified regions<\/td><\/tr><tr><td><strong>Gan &amp; Lee Responsibilities<\/strong><\/td><td>Manufacturing supply and related matters<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Leverages Sandoz&#8217;s established European diabetes market access and payer relationships<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biosimilar Market Entry:<\/strong> Bysumlog and Dazparda will be among the <strong>first insulin biosimilars<\/strong> in the EU, targeting the <strong>\u20ac\u202f2\u202fbillion+ European rapid\u2011acting insulin market<\/strong> dominated by originators.<\/li>\n\n\n\n<li><strong>Pricing Pressure:<\/strong> Biosimilar entry is expected to drive <strong>20\u201340% price reductions<\/strong>, improving patient access while capturing market share from Lilly and Novo Nordisk.<\/li>\n\n\n\n<li><strong>China\u2011EU Biopharma Export:<\/strong> CHMP positive opinion validates Gan &amp; Lee&#8217;s <strong>manufacturing quality<\/strong> and <strong>regulatory capabilities<\/strong>, supporting broader <strong>global biosimilar expansion<\/strong>.<\/li>\n\n\n\n<li><strong>Sandoz Partnership Synergy:<\/strong> Collaboration with <strong>Europe&#8217;s leading generics\/biosimilars player<\/strong> de\u2011risks commercial execution and accelerates formulary access across diverse reimbursement systems.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>European Insulin Market<\/strong><\/td><td>~\u202f\u20ac\u202f5\u202fbillion total; rapid\u2011acting segment ~\u202f40% share; high originator concentration<\/td><\/tr><tr><td><strong>Biosimilar Uptake Drivers<\/strong><\/td><td>Automatic substitution policies in multiple EU states; cost\u2011containment pressure on national health systems<\/td><\/tr><tr><td><strong>Gan &amp; Lee Positioning<\/strong><\/td><td>First Chinese insulin manufacturer to achieve EMA positive opinion; establishes quality benchmark for domestic biopharma<\/td><\/tr><tr><td><strong>Competitive Dynamics<\/strong><\/td><td>Mylan\/Viatris, Biocon, and others advancing insulin biosimilars; Gan &amp; Lee\/Sandoz combination provides strong competitive positioning<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding EC final approval timelines, commercial launch dates, and market share capture. Actual results may differ due to risks including originator pricing responses, automatic substitution policy variations, and manufacturing supply consistency.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gan &amp; Lee Pharmaceuticals (SHA:\u202f603087) and its European subsidiary Gan &amp; Lee Europe announced that&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58313,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,39,421,38,1120],"class_list":["post-58311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biosimilars","tag-diabetes","tag-gan-lee-pharmaceuticals","tag-market-approval-filings","tag-sha-603087"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gan &amp; Lee&#039;s Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gan &amp; Lee Pharmaceuticals (SHA:\u202f603087) and its European subsidiary Gan &amp; Lee Europe announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval for two insulin biosimilars: Bysumlog (insulin lispro) and Dazparda (insulin aspart). Upon European Commission (EC) ratification, the products will be marketed across EU member states plus Iceland, Liechtenstein, and Norway, providing biosimilar alternatives to Eli Lilly&#039;s Humalog and Novo Nordisk&#039;s NovoRapid.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58311\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gan &amp; Lee&#039;s Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry\" \/>\n<meta property=\"og:description\" content=\"Gan &amp; Lee Pharmaceuticals (SHA:\u202f603087) and its European subsidiary Gan &amp; Lee Europe announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval for two insulin biosimilars: Bysumlog (insulin lispro) and Dazparda (insulin aspart). Upon European Commission (EC) ratification, the products will be marketed across EU member states plus Iceland, Liechtenstein, and Norway, providing biosimilar alternatives to Eli Lilly&#039;s Humalog and Novo Nordisk&#039;s NovoRapid.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58311\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-27T12:09:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-27T12:09:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2706.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gan &amp; Lee&#8217;s Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry\",\"datePublished\":\"2026-02-27T12:09:42+00:00\",\"dateModified\":\"2026-02-27T12:09:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2706.webp\",\"keywords\":[\"Biosimilars\",\"Diabetes\",\"Gan &amp; Lee Pharmaceuticals\",\"Market approval filings\",\"SHA: 603087\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58311#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58311\",\"name\":\"Gan &amp; Lee's Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2706.webp\",\"datePublished\":\"2026-02-27T12:09:42+00:00\",\"dateModified\":\"2026-02-27T12:09:43+00:00\",\"description\":\"Gan & Lee Pharmaceuticals (SHA:\u202f603087) and its European subsidiary Gan & Lee Europe announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval for two insulin biosimilars: Bysumlog (insulin lispro) and Dazparda (insulin aspart). Upon European Commission (EC) ratification, the products will be marketed across EU member states plus Iceland, Liechtenstein, and Norway, providing biosimilar alternatives to Eli Lilly's Humalog and Novo Nordisk's NovoRapid.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58311\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2706.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2706.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gan & Lee Bysumlog Dazparda\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58311#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gan &amp; Lee&#8217;s Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gan &amp; Lee's Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry - Insight, China&#039;s Pharmaceutical Industry","description":"Gan & Lee Pharmaceuticals (SHA:\u202f603087) and its European subsidiary Gan & Lee Europe announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval for two insulin biosimilars: Bysumlog (insulin lispro) and Dazparda (insulin aspart). Upon European Commission (EC) ratification, the products will be marketed across EU member states plus Iceland, Liechtenstein, and Norway, providing biosimilar alternatives to Eli Lilly's Humalog and Novo Nordisk's NovoRapid.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58311","og_locale":"en_US","og_type":"article","og_title":"Gan &amp; Lee's Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry","og_description":"Gan & Lee Pharmaceuticals (SHA:\u202f603087) and its European subsidiary Gan & Lee Europe announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval for two insulin biosimilars: Bysumlog (insulin lispro) and Dazparda (insulin aspart). Upon European Commission (EC) ratification, the products will be marketed across EU member states plus Iceland, Liechtenstein, and Norway, providing biosimilar alternatives to Eli Lilly's Humalog and Novo Nordisk's NovoRapid.","og_url":"https:\/\/flcube.com\/?p=58311","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-27T12:09:42+00:00","article_modified_time":"2026-02-27T12:09:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2706.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58311#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58311"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gan &amp; Lee&#8217;s Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry","datePublished":"2026-02-27T12:09:42+00:00","dateModified":"2026-02-27T12:09:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58311"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58311#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2706.webp","keywords":["Biosimilars","Diabetes","Gan &amp; Lee Pharmaceuticals","Market approval filings","SHA: 603087"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58311#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58311","url":"https:\/\/flcube.com\/?p=58311","name":"Gan &amp; Lee's Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58311#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58311#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2706.webp","datePublished":"2026-02-27T12:09:42+00:00","dateModified":"2026-02-27T12:09:43+00:00","description":"Gan & Lee Pharmaceuticals (SHA:\u202f603087) and its European subsidiary Gan & Lee Europe announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval for two insulin biosimilars: Bysumlog (insulin lispro) and Dazparda (insulin aspart). Upon European Commission (EC) ratification, the products will be marketed across EU member states plus Iceland, Liechtenstein, and Norway, providing biosimilar alternatives to Eli Lilly's Humalog and Novo Nordisk's NovoRapid.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58311#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58311"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58311#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2706.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2706.webp","width":1080,"height":608,"caption":"Gan & Lee Bysumlog Dazparda"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58311#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gan &amp; Lee&#8217;s Insulin Biosimilars Win CHMP Positive Opinion \u2013 Bysumlog and Dazparda Near EU Market Entry"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2706.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58311"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58311\/revisions"}],"predecessor-version":[{"id":58314,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58311\/revisions\/58314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58313"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}